BlackRock Health Sciences Trust (BME) Fair Value & Analysis
Financial Services · US · Market cap $570M · ISIN US09250W1071
What is BlackRock Health Sciences Trust really worth?
BlackRock Health Sciences Trust
BME · US
A solid business, trading 41% below our fair value of $77.42.
As of Aug 16, 2026, the fair value of BlackRock Health Sciences Trust is $77.42 per share against a price of $45.81, so the fair value sits 69% above the price. A model estimate blended from multiple valuation models, recalculated regularly.
Strengths
Risks
For context
Fair value as of: Aug 16, 2026
From 8 valuation models · updated 21 days ago
Share price +6.1% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- Solid quality (65/100) at a price below fair value, the discount is the argument here, not the business quality.
- A fairly wide model range ($41.12 to $96.78) leaves room in how you read the outcome.
- For a financial, book-value and earnings-based methods matter more than a cash-flow DCF, which fits banks and insurers poorly.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 16, 2026.
How to read this chart
60‑month range $28.83 – $46.28 · fair‑value band $41.12 – $96.78 · the $45.81 price screens below the $77.42 fair value. Dashed = 300-day average. As of Aug 16, 2026.
Analysis
BlackRock Health Sciences Trust (BME) currently trades at $45.81, while our model-based Fair Value estimate is $77.42, implying the stock looks roughly 40.8% undervalued today. The Quality Score stands at 65/100 (solid quality), in the Financial Services sector. Bull case: the Earnings-Based group reads highest at a median of $208.44 per share, and 5 of the 8 models we run sit above the $45.81 price. Bear case: the Asset-Based group reads lowest at $29.46, and 3 of the 8 models stay below the price. Evidence for this calculation is high.
Revenue grew 7.6% year over year. It earns a return on equity of 13.8%. The stock trades on a trailing P/E of 7.7. Fundamentals as of Aug 16, 2026
Our scenario range runs from $41.12 (bear case) to $96.78 (bull case); at $45.81, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high and 41% above its 52-week low, currently above its 200-day average. For context, the median of 10 Financial Services peers we cover trades at −28% fair-value upside, at 69%, BME screens cheaper than that median.
Fair Value models
This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly $1.89 per share. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 8 models by family
Widest divergence: Earnings-Based ($208.44) versus Asset-Based ($29.46). Highest evidence: Residual Income (72).
Notify me when BME reaches fair value
Put BME on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 16, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 58 · Market factors (momentum, volatility) 79
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
BlackRock Health Sciences Trust is a closed-ended equity mutual fund launched by BlackRock, Inc. The fund is managed by BlackRock Advisors, LLC. It invests in the public equity markets of the United States.
Full company description
BlackRock Health Sciences Trust is a closed-ended equity mutual fund launched by BlackRock, Inc. The fund is managed by BlackRock Advisors, LLC. It invests in the public equity markets of the United States. The fund seeks to invest in stocks of companies operating in the health sciences and related sectors, which include businesses involved in researching, developing, producing, distributing or delivering medical, dental, optical, pharmaceutical or biotechnology products, supplies, equipment, or services. It also invests through equity derivatives, with an emphasis on option writing. The fund benchmarks the performance of its portfolio against the Russell 3000 Healthcare Index. BlackRock Health Sciences Trust was formed on March 31, 2005 and is domiciled in the United States.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
BlackRock Health Sciences Trust reported revenue of $36.2M in FY2025 versus $59.7M in FY2021, a compound −11.8%/yr. Reported net income was $77.0M in FY2025, compounding +6.8%/yr from FY2021.
of which total revenue +32.3 % · buybacks/dilution −19.9 %
Annual growth per factor. These are factors, not summands: multiplied they give the EPS growth rate, added they do not quite. Start and end points are 3-year averages (details on hover).
Watch BME: get an alert when its fair value changes →
Peer Group
Asset Management · 695 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Asset Management median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Asset Management stocks, each showing price versus our Fair Value estimate (as of Aug 16, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Blackstone Inc BX | $142.39 | $52.88 | −63% |
| Investor AB INVEB | kr 408.05 | kr 827.56 | +103% |
| Brookfield Corporation BN | C$55.74 | C$10.67 | −81% |
| KKR & Co KKR | $108.68 | $19.97 | −82% |
| Apollo Global Management, Inc APO | $135.04 | $101.04 | −25% |
| State Street Corporation STT | $193.33 | $138.33 | −28% |
| Ameriprise Financial, Inc AMP | $559.32 | $515.24 | −8% |
| Ares Management Corporation ARES | $143.10 | $30.88 | −78% |
| Northern Trust Corporation NTRS | $186.79 | $122.02 | −35% |
| Raymond James Financial, Inc RJF | $181.10 | $142.42 | −21% |
Compare BlackRock Health Sciences Trust with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Financial Services stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is BlackRock Health Sciences Trust (BME) overvalued or undervalued?
What is the fair value of BME?
What is the quality score of BME?
What is the price target for BlackRock Health Sciences Trust (BME)?
What is the BlackRock Health Sciences Trust stock forecast for 2026?
Does BlackRock Health Sciences Trust pay a dividend?
Watch BlackRock Health Sciences Trust in the live analysis
One click puts BlackRock Health Sciences Trust on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.